Publication details
PSIKET DEVELOPMENT SAFETY UPDATE REPORT Psilocybin versus ketamin – strategie rychlé antidepresivní odpovědi u deprese rezistentní k léčbě Období: 22.7.2023 – 21.7.2024
| Title in English | PSIKET DEVELOPMENT SAFETY UPDATE REPORT Psilocybin versus ketamine – a strategy for rapid antidepressant response in treatment-resistant depression Period: 22.7.2023 – 21.7.2024 |
|---|---|
| Authors | |
| Year of publication | 2024 |
| Type | Research report |
| MU Faculty or unit | |
| web | |
| Description | The second periodic report for the PSIKET_002CZE study evaluates the safety data received by the study sponsor during the period from 22.7.2023 to 21.7.2024. The clinical trial is multicenter with centers at the National Institute of Mental Health in Klecany and the Masaryk Institute of Oncology in Brno. The clinical trial PSIKET_002CZE is focused on studying the antidepressant effect of the natural alkaloid psilocybin in a population of patients with depressive disorder that accompanies oncological disease (comorbid depression). The effect is compared with control substances with acute short-term antidepressant effect (with ketamine) and without antidepressant effect (with midazolam). |